Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma

[1]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[2]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[3]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Gettinger,et al.  First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status , 2014 .

[5]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[6]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[7]  G. Linette,et al.  LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY , 2014 .

[8]  J. Wolchok,et al.  Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Prashanth M. Thalanayar,et al.  Melanoma adjuvant therapy. , 2014, Hematology/oncology clinics of North America.

[10]  J. Taube,et al.  Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. , 2014 .

[11]  J. Lunceford,et al.  Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. , 2014 .

[12]  S. Gettinger,et al.  First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. , 2014 .

[13]  C. Horak,et al.  Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[15]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Kirkwood,et al.  PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1 , 2009, The Journal of Immunology.

[17]  Vrajesh V. Parekh,et al.  PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells1 , 2009, The Journal of Immunology.

[18]  Jianzhu Chen,et al.  B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation , 2009, Proceedings of the National Academy of Sciences.

[19]  M. Sayegh,et al.  Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells , 2008, Proceedings of the National Academy of Sciences.

[20]  H. Samaratunga,et al.  Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs) , 2008, Journal of Biological Chemistry.

[21]  G. Zhu,et al.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. , 2008, Blood.

[22]  Changping Wu,et al.  [Expression and clinical significance of costimulatory molecule B7-H3 mRNA and B7-H3 protein in gastric carcinoma]. , 2007, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.

[23]  Koichiro Matsumoto,et al.  Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers , 2007, Cancer Immunology, Immunotherapy.

[24]  Haidong Dong,et al.  PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.

[25]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[26]  L. Lacombe,et al.  879: PD-L1 (B7-H1) Expression by Urothelial Carcinoma of the Bladder and BCG-Induced Granulomata: Associations with Localized Stage Progression , 2007 .

[27]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[28]  T. Okazaki,et al.  The PD-1-PD-L pathway in immunological tolerance. , 2006, Trends in immunology.

[29]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[30]  J. Cheville,et al.  Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma , 2005, Cancer.

[31]  J. Cheville,et al.  618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target , 2005 .

[32]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[33]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[34]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[35]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[36]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[40]  I. Judson,et al.  Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. , 1997, The Journal of pharmacology and experimental therapeutics.

[41]  C. Balch,et al.  A Multifactorial Analysis of Melanoma: III. Prognostic Factors in Melanoma Patients with Lymph Node Metastases (Stage II) , 1981, Annals of surgery.

[42]  M. Mandalà,et al.  Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. , 2014, Critical reviews in oncology/hematology.

[43]  日野 亮介.  Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma , 2010 .

[44]  G. Nuovo,et al.  Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. , 2006, Cancer research.

[45]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[46]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.